 The secondary efficacy criteria will be i the maintenance of regulatory T cells during the 6 months of treatment with IL-2 vs. placebo and ii the stabilization or regression of the disease as determined by disease activity parameters assessed by MRI cumulative number of new lesions in T1 enhanced by gadolinium after 6 months in the groups treated with IL-2 compared to placebo. 